Jagroop Singh Doad, DO

PGY-1 IM @CorewellHealth @michiganstateu | @ACCinTouch National Resident Leadership Co-Chair | @SafeBeat Research | @Campbell__Med @WesternU | 🇺🇸🇨🇦

[Rachita Navara, MD, FACC, FHRS @DrRachitaEP]

Energizing #ACC26: 4 @SafeBeat presentations, co-chairing AI in EP session we proposed with this ⭐️ cast, and official FACC hooding - full circle moment from high school anatomy, lying awake excited by my own heart pumping. Excited to keep advancing #AFib care @ACCinTouch

[Jagroop Singh Doad, DO @DoadJagroop]

Thanks for a great weekend, NOLA! It was awesome catching up with old friends and having a great time with my co-residents. Looking forward to Houston!

[C. Michael Gibson MD @CMichaelGibson]

STEMI-DTU trial: Combination of the Impella CP plus device a 30-minute delay to PCI did not reduce infarct size vs. immediate PCI in patients with anterior STEMI without shock. #ACC26 View slides here: https://t.co/yzmg7CwT0k

[Jagroop Singh Doad, DO @DoadJagroop]

Thankful to @SafeBeat to have been part of 3 abstracts being presented at ACC this year. See you all in NOLA soon! @corsi_douglas 🫀 #ACC26

[Gurleen Kaur, MD @Gurleen_Kaur96]

Don’t miss the first official @CardioNerds 5K at #ACC2026

⏰ Sun March 29, 6:45 AM

🔗 Sign up here: https://t.co/R2EeN1Y7eI

Not a runner? No problem - walkers (like me!) are welcome! Come join us at the riverfront 🫀

[American College of Cardiology @ACCinTouch]

Artie is packed, pumped, and super excited for #ACC26! ✈️

Pro tip: Use the ACC.26 planning tools to plan your experience ahead of time. 📲 Download the ACC.26 App and get everything you need to navigate the meeting with ease. 🔗 https://t.co/efORTQvSoK

See you all in NOLA! 🎷

[NEJM @NEJM]

In the phase 3 CORALreef Lipids trial, the oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by 57% at 24 weeks and also lowered non-HDL cholesterol, apolipoprotein B, and lipoprotein(a). Adverse events were similar in the two groups. Full trial results and Research Summary: https://t.co/o5RS02KCWi

[Davide Capodanno @DFCapodanno]

After the two recent meta-analyses published in The Lancet and NEJM, one could argue that the case is settled: following myocardial infarction, beta-blockers should be prescribed to patients with an LVEF <40%, may be considered in those with an LVEF of 40–49%, and in patients with an LVEF ≥50% only if there are other indications, such as hypertension, atrial fibrillation, or heart failure. The guidelines are partially misaligned with the emerging evidence and will most likely be updated in the near future.

[Frederik Meijer Heart & Vascular Institute @FM_HVI]

Congrats to Dr. @drsjdan and Dr. @NagibChalfoun and the Corewell Health electrophysiology team for their leadership in the largest safety study of Pulsed Field Ablation - 40,000+ patients nationwide. ❤️⚡️
📖 Read the publication: https://t.co/o1mCwvL1Tj

[Anu Lala (Anuradha Lala-Trindade) @dranulala]

I liked this 📰 a lot @CircAHA :

Exercise &amp; CBT after Takotsubo CM
The simple stuff makes a difference.

CLINICAL IMPLICATIONS?
Behavioral modification strategies can enhance the metabolic &amp; functional recovery of 🫀, supporting the use of these rehab in a unique pop!

[Jagroop Singh Doad, DO @DoadJagroop]

Excited to be participating in the #AMAResearchChallenge poster symposium Oct. 22- 23! Thank you to @SafeBeat for the opportunity. Register to view my poster, and explore other top research projects from medical students and residents: https://t.co/gOz9dJoeFD @AmerMedicalAssn

[Muthu Vaduganathan @mvaduganathan]

🔥 New in @NatureMedicine

How do you communicate lifetime benefits expected with HFpEF therapies?

New data from 3 RCTs (#DELIVER #FINEARTS #PARAGON) estimate up to *5 years* of event-free survival w combination Rx

#GDMT for HFpEF has finally arrived!

🔗https://t.co/ozSx3UwkLN

[NEJM @NEJM]

In patients with heart failure and reduced ejection fraction who were receiving guideline-directed medical therapy, digitoxin lowered the risk of death or hospitalization for heart failure as compared with placebo. Full DIGIT-HF phase 4 trial results and Research Summary: https://t.co/qak9UrgAhz

[Srihari S. Naidu, MD @SrihariNaiduMD]

Here’s the two key slides. Please share! What is @SCAI DLC and how to use it! #scaishock2025 #SCAIShock

@mirvatalasnag @djc795 @CMichaelGibson @DLBHATTMD @Hragy @RameshDaggubati

[Rachita Navara, MD, FACC, FHRS @DrRachitaEP]

#HRX2025 was a blast! Thrilled to share how @SafeBeat is bringing AI to real clinical workflows, from QTc to AF drug dosing. Huge thanks to @HRSonline @experienceHRX and the #EPeeps for keeping the digital heart health revolution alive.

[Andrew J Sauer MD @AndrewJSauer]

The vast majority of patients with HFpEF have cardiometabolic disease driven by adipose tissue at the core.

Lines of evidence continue to support this adipokine hypothesis.

The inimitable Milton Packer provides a deeper understanding of the evidence in this timely perspective piece in JACC.

https://t.co/9HSsLJnNOI

[Amanpreet Singh Wasir, MBBS @amanpreet_wasir]

@MountSinaiHeart @UWMedicine @DrEugeneYang @DrGaganSahni @ACCinTouch @JACCJournals @ACCmediacenter @worldheartfed @ErsozluSara @EspicheCarlos @MiloRaslan @MaximaMendez15 Just wrapped up a session on metastatic adrenal cortical carcinoma &amp; refractory HTN post-adrenalectomy 🩺

🔹 Chemo = mainstay, but limited
by hormones &amp; toxicity
🔹 Surgery remains key despite
recurrence risk

@DrGaganSahni @MountSinaiHeart

#CardioX #MedTwitter #ESCCongress

[Ritika Tuli @RitikaTuliMD]

💡 #CardioNugget
LVEDP vs PCWP

-LVEDP: measured during left heart cath, it’s the pressure in the LV at end-diastole (filling).
-PCWP: measured during right heart cath, wedging the PA catheter “looks back” at the LA.
👉 Normally: PCWP ≈ LVEDP (6–12 mmHg)
Both reflect LV filling pressures, and are used to quantify congestion

🚨 Not equal if there’s a block/mismatch between LA & LV:
-Mitral stenosis → ↑PCWP, normal LVEDP
-Stiff LV/diastolic dysfunction → LVEDP >> PCWP

#CardioNuggets #MedEd #FOAMed #CardioTwitter

[CardioVisual: Powered by MedicalVisual @CardioVisualApp]

At @ASPCardio 2025, Dr. Danielle Belardo @DBelardoMD says 99% of supplements = ‘expensive urine’😬💊
Full interview coming soon.
#ASPC2025 #CardioTwitter #EvidenceBasedCare

[Muthu Vaduganathan @mvaduganathan]

Wow, the game has changed! #SURPASSCVOT meets its primary &amp; secondary endpoints in first *head-to-head* CV outcomes trial!

Tirzepatide (dual GLP1/GIP agonist) vs Dulaglutide (GLP-1RA)

including 16% lower risk of all cause mortality!

https://t.co/rUFYZVn41N